Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Quiet Board

<< Previous

Bullboard Posts

Next >>

Comment by Stocker46on Mar 14, 2021 12:57pm

107 Views

Post# 32795108

RE:RE:RE:Quiet Board

Correct, the impairment charge is a non-cash entry.

It's kind of like spending $8 - $ 9 million on a fixed asset to be amortized over 15 or 20 years. Then you find out a year & a half later that it's totally useless and are forced to write it off ... and that you'll be required to pay an undetermined amount of cash to get rid of it.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec